a public good project by the
Synthesis
Company
of California

© 2026

David M. Goldenberg | doi.page

0 works0 citations0 h-index

David M. Goldenberg

Publications by Year

Research Areas

Monoclonal and Polyclonal Antibodies Research, Radiopharmaceutical Chemistry and Applications, Lymphoma Diagnosis and Treatment, HER2/EGFR in Cancer Research, CAR-T cell therapy research

Most-Cited Works

→ Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer(2021)1,447 cited
→ Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer(2019)825 cited
→ Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning(1978)756 cited
→ A Review of Tissue Substitutes for Ultrasound Imaging(2010)645 cited
→ Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*(2015)458 cited
→ A Novel Method of 18F Radiolabeling for PET(2009)402 cited

→ Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer(2017)

396 cited

→ Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial(2021)355 cited

→ Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy(2005)350 cited

→ First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors(2015)341 cited